Last reviewed 2026-05-23 · How we verify

SoluMatrix™ Abiraterone Acetate

GU Research Network, LLC · Phase 3 active Small molecule Under review

SoluMatrix™ Abiraterone Acetate is a CYP17 inhibitor Small molecule drug developed by GU Research Network, LLC. It is currently in Phase 3 development for Metastatic castration-resistant prostate cancer, Non-metastatic castration-resistant prostate cancer. Also known as: Yonza, SoluMatrix™.

Abiraterone acetate is a CYP17 inhibitor that blocks the production of androgens, such as testosterone, in the body.

SoluMatrix Abiraterone Acetate is a small molecule inhibitor of the cytochrome P450 17A1 enzyme, specifically targeting steroid 17-alpha-hydroxylase/17,20 lyase. It is used to treat prostate cancer, as indicated by clinical trials registered on ClinicalTrials.gov.

Likelihood of approval

61.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Oncology Phase 3 boost +3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	SoluMatrix™ Abiraterone Acetate
Also known as	Yonza, SoluMatrix™
Sponsor	GU Research Network, LLC
Drug class	CYP17 inhibitor
Target	CYP17
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

By inhibiting CYP17, abiraterone acetate reduces the levels of androgens, which can slow the growth of prostate cancer cells. This mechanism is particularly effective in treating castration-resistant prostate cancer.

Approved indications

Metastatic castration-resistant prostate cancer
Non-metastatic castration-resistant prostate cancer

Common side effects

Adrenal insufficiency
Hypertension
Fatigue
Diarrhea
Nausea

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SoluMatrix™ Abiraterone Acetate CI brief — competitive landscape report
SoluMatrix™ Abiraterone Acetate updates RSS · CI watch RSS
GU Research Network, LLC portfolio CI

Frequently asked questions about SoluMatrix™ Abiraterone Acetate

What is SoluMatrix™ Abiraterone Acetate?

SoluMatrix™ Abiraterone Acetate is a CYP17 inhibitor drug developed by GU Research Network, LLC, indicated for Metastatic castration-resistant prostate cancer, Non-metastatic castration-resistant prostate cancer.

How does SoluMatrix™ Abiraterone Acetate work?

Abiraterone acetate is a CYP17 inhibitor that blocks the production of androgens, such as testosterone, in the body.

What is SoluMatrix™ Abiraterone Acetate used for?

SoluMatrix™ Abiraterone Acetate is indicated for Metastatic castration-resistant prostate cancer, Non-metastatic castration-resistant prostate cancer.

Who makes SoluMatrix™ Abiraterone Acetate?

SoluMatrix™ Abiraterone Acetate is developed by GU Research Network, LLC (see full GU Research Network, LLC pipeline at /company/gu-research-network-llc).

Is SoluMatrix™ Abiraterone Acetate also known as anything else?

SoluMatrix™ Abiraterone Acetate is also known as Yonza, SoluMatrix™.

What drug class is SoluMatrix™ Abiraterone Acetate in?

SoluMatrix™ Abiraterone Acetate belongs to the CYP17 inhibitor class. See all CYP17 inhibitor drugs at /class/cyp17-inhibitor.

What development phase is SoluMatrix™ Abiraterone Acetate in?

SoluMatrix™ Abiraterone Acetate is in Phase 3.

What are the side effects of SoluMatrix™ Abiraterone Acetate?

Common side effects of SoluMatrix™ Abiraterone Acetate include Adrenal insufficiency, Hypertension, Fatigue, Diarrhea, Nausea.

What does SoluMatrix™ Abiraterone Acetate target?

SoluMatrix™ Abiraterone Acetate targets CYP17 and is a CYP17 inhibitor.

Drug class: All CYP17 inhibitor drugs
Target: All drugs targeting CYP17
Manufacturer: GU Research Network, LLC — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Metastatic castration-resistant prostate cancer
Indication: Drugs for Non-metastatic castration-resistant prostate cancer
Also known as: Yonza, SoluMatrix™

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing